Darifenacin: a novel M₃ muscarinic selective receptor antagonist for the treatment of overactive bladder

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.13, Iss.11, 2004-11, pp. : 1493-1500

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Darifenacin: In the Treatment of Overactive Bladder

By Katherine F. Croom Gillian M. Keating

Drugs & Aging, Vol. 21, Iss. 13, 2004-01 ,pp. : 885-892

Adis International

Access to resources Recommend Favorite

The (S)-(+)-enantiomer of dimethindene: a novel M 2 -selective muscarinic receptor antagonist

By Pfaff O. Hildebrandt C. Waelbroeck M. Xue H. Moser U. Mutschler E. Lambrecht G.

European Journal of Pharmacology, Vol. 286, Iss. 3, 1995-11 ,pp. : 229-240

Elsevier

Access to resources Recommend Favorite

Novel, highly selective, muscarinic M3 receptor antagonists

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 9, 2001-09 ,pp. : 1475-1478

Informa Healthcare

Access to resources Recommend Favorite

Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites?

By Michel Martin Hegde Sharath

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 374, Iss. 2, 2006-11 ,pp. : 79-85

Springer Publishing Company

Access to resources Recommend Favorite

Darifenacin improves symptoms in overactive bladder

Inpharma, Vol. 1, Iss. 1449, 2004-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite